Sugi Predict

Sugi Predict / Targets / P4HTM

P4HTM

Transmembrane prolyl 4-hydroxylase · Q9NXG6 · P4HTM on Sugi Atlas →

39,552 patent compounds predicted against P4HTM, 25,378 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL64700 SCHEMBL64700 0.66 17/20
SCHEMBL63831 SCHEMBL63831 0.56 17/20
SCHEMBL128459 SCHEMBL128459 0.67 15/20
SCHEMBL129542 SCHEMBL129542 0.59 15/20
SCHEMBL257248 SCHEMBL257248 0.59 15/20
SCHEMBL363525 SCHEMBL363525 0.62 14/20
SCHEMBL288224 SCHEMBL288224 0.61 14/20
Pyridine-2,5-Dicarboxylic Acid Pyridine-2,5-Dicarboxylic Acid (SCHEMBL70231) 1.00 13/20
Pyridine-2,5-Dicarboxylic Acid Pyridine-2,5-Dicarboxylic Acid (SCHEMBL336436) 0.95 13/20
SCHEMBL287277 SCHEMBL287277 0.69 13/20
SCHEMBL110129 SCHEMBL110129 0.59 13/20
Methane Methane (SCHEMBL364091) 0.55 12/20
SCHEMBL286868 SCHEMBL286868 0.67 11/20
SCHEMBL69566 SCHEMBL69566 0.63 11/20
SCHEMBL82620 SCHEMBL82620 0.59 11/20
SCHEMBL157288 SCHEMBL157288 0.59 11/20
SCHEMBL249720 SCHEMBL249720 0.59 11/20
SCHEMBL362304 SCHEMBL362304 0.58 10/20
SCHEMBL64528 SCHEMBL64528 0.53 10/20
Acipimox Acipimox (SCHEMBL48922) 0.38 10/20

Clinical trials — most relevant to P4HTM by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies PHASE4COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Study of the Effects of Iron on Lung Blood Pressure at High Altitude PHASE2WITHDRAWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease PHASE1/PHASE2COMPLETED
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome PHASE2WITHDRAWN
Problems With Morphine Use in Patients With a Severe Brain Injury PHASE1/PHASE2UNKNOWN
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) PHASE2UNKNOWN
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery nanCOMPLETED
Genes-in-Action - Hepcidin Regulation of Iron Supplementation nanCOMPLETED
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease nanCOMPLETED
Hemochromatosis and Iron Overload Screening Study (HEIRS) nanCOMPLETED
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Study of the Effects of Iron Levels on the Lungs at High Altitude nanCOMPLETED
Mitochondrial Function of Immune Cells in Sepsis nanCOMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Elucidating the Molecular and Biochemical Basis of the Human AhR-mutation Disease nanUNKNOWN
Identification of Acute Intermittent Porphyria Modifying Genes nanRECRUITING
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity nanCOMPLETED
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis nanUNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension nanCOMPLETED
Inherited Reproductive Disorders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a P4HTM binder may also engage these)

ProteinNameSimilarity
Q8BG58 — 1.000 Q8BG58 →
Q9EPI0 — 0.971 Q9EPI0 →
Q5QQ51 — 0.970 Q5QQ51 →
Q5QQ49 — 0.969 Q5QQ49 →
Q9H1B5 — 0.969 Q9H1B5 →
Q6L9W6 — 0.967 Q6L9W6 →
Q80XH4 — 0.967 Q80XH4 →
Q6L8S8 — 0.967 Q6L8S8 →
Q7LGC8 — 0.967 Q7LGC8 →
Q658N2 — 0.965 Q658N2 →
Q5NDF2 — 0.965 Q5NDF2 →
Q9QZL2 — 0.965 Q9QZL2 →
Q505J3 — 0.964 Q505J3 →
Q5STE3 — 0.964 Q5STE3 →
Q92179 — 0.963 Q92179 →
P17246 — 0.963 P17246 →
Q8R4K8 — 0.963 Q8R4K8 →
O88199 — 0.963 O88199 →
Q66PG4 — 0.963 Q66PG4 →
Q8BW41 — 0.963 Q8BW41 →
Q5NDE9 — 0.962 Q5NDE9 →
Q8CHI9 — 0.962 Q8CHI9 →
Q6MZW2 — 0.962 Q6MZW2 →
Q29043 — 0.962 Q29043 →
P54831 — 0.962 P54831 →
Q9EPL0 — 0.962 Q9EPL0 →
O19011 — 0.961 O19011 →
Q5NDF0 — 0.961 Q5NDF0 →
Q5QQ50 — 0.961 Q5QQ50 →
Q5XGE0 — 0.961 Q5XGE0 →